NFKB1 and neoplasm: One study found that sulindac downregulates PD-L1 by blocking the NF-κB signaling pathway, thereby reducing the amount of exosomal PD-L1 secreted by tumor cells and enhancing the efficacy of PD-L1 immunotherapy in CRC patients with the pMMR phenotype234.